AstraZeneca PLC reported strong financial performance for the nine months ending September 30, 2024, with total revenue rising by 19% to $39.18 billion and core EPS increasing by 11% to $6.12; the company has raised its full-year revenue and core EPS guidance, reflecting continued growth momentum. The report includes details on product sales and recent regulatory approvals in the U.S. and China, emphasizing a solid outlook for the remainder of 2024.